"Enoxaparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed)
Concept/Terms
PK-10,169- PK-10,169
- PK 10,169
- PK10,169
- PK-10169
- PK 10169
- PK10169
Below are MeSH descriptors whose meaning is more general than "Enoxaparin".
Below are MeSH descriptors whose meaning is more specific than "Enoxaparin".
This graph shows the total number of publications written about "Enoxaparin" by people in Harvard Catalyst Profiles by year, and whether "Enoxaparin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 1 | 4 |
| 1999 | 3 | 2 | 5 |
| 2000 | 7 | 1 | 8 |
| 2001 | 10 | 2 | 12 |
| 2002 | 11 | 6 | 17 |
| 2003 | 7 | 1 | 8 |
| 2004 | 8 | 2 | 10 |
| 2005 | 8 | 2 | 10 |
| 2006 | 6 | 1 | 7 |
| 2007 | 11 | 6 | 17 |
| 2008 | 7 | 3 | 10 |
| 2009 | 5 | 3 | 8 |
| 2010 | 5 | 2 | 7 |
| 2011 | 5 | 2 | 7 |
| 2012 | 3 | 6 | 9 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 4 | 3 | 7 |
| 2016 | 2 | 3 | 5 |
| 2017 | 6 | 5 | 11 |
| 2018 | 3 | 3 | 6 |
| 2019 | 3 | 1 | 4 |
| 2020 | 4 | 3 | 7 |
| 2021 | 5 | 1 | 6 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 3 | 3 |
Below are the most recent publications written about "Enoxaparin" by people in Profiles.
-
Limited Effect of Prevention Strategies on Incidence of Clinically Detectable Venous Thromboembolism After Lung Transplantation. Transplant Proc. 2023 Nov; 55(9):2191-2196.
-
Closer to FREEDOM From Uncertainty. J Am Coll Cardiol. 2023 05 09; 81(18):1763-1765.
-
Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19. J Am Coll Cardiol. 2023 05 09; 81(18):1747-1762.
-
External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial. J Thromb Thrombolysis. 2023 Feb; 55(2):211-221.
-
Adrenal infarction secondary to methamphetamine use: a case report and review of the literature. J Med Case Rep. 2022 Oct 18; 16(1):379.
-
In Silico Analysis of the Antagonist Effect of Enoxaparin on the ApoE4-Amyloid-Beta (Aß) Complex at Different pH Conditions. Biomolecules. 2022 03 25; 12(4).
-
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol. 2022 03 08; 79(9):917-928.
-
Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. Thromb Res. 2022 Mar; 211:63-69.
-
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021 12 01; 181(12):1612-1620.
-
Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. Inflamm Res. 2022 Jan; 71(1):39-56.